Dana T. Aftab, Ph.D., is a distinguished scientist and executive who currently holds the position of Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer at Exelixis, Inc. Dr. Aftab's professional journey is marked by significant contributions to the field of oncology and drug discovery. She earned her Ph.D. in Pharmacology from the University of California, San Diego, and has since built an impressive career in both academia and the pharmaceutical industry. Before joining Exelixis, Dr. Aftab held key leadership roles at companies such as Celgene Corporation, where she was instrumental in advancing oncology drug development programs. At Exelixis, Dr. Aftab plays a pivotal role in steering the company's research and development efforts. Her responsibilities encompass overseeing the discovery and translational research initiatives, which are crucial for advancing Exelixis' pipeline of innovative cancer therapies. Under her leadership, Exelixis has made significant strides in developing and commercializing targeted therapies, notably with the success of cabozantinib, a multi-kinase inhibitor used in the treatment of various cancers. Dr. Aftab's strategic vision and scientific expertise have been vital in fostering collaborations and driving the company's mission to improve patient outcomes through cutting-edge research. Dr. Aftab's achievements extend beyond her corporate role, as she is also an active member of the scientific community. She has authored numerous peer-reviewed publications and is a frequent speaker at international conferences, sharing her insights on the latest advancements in cancer research. Her dedication to advancing the field of oncology has earned her recognition and respect among her peers. As the Chief Scientific Officer at Exelixis, Dr. Aftab continues to lead with a focus on innovation, collaboration, and patient-centric research, solidifying her reputation as a leader in the biopharmaceutical industry.